Fresenius Medical Care (FMS) Cut to Equal Weight at Morgan Stanley
Fresenius Medical Care (NYSE:FMS) was downgraded by investment analysts at Morgan Stanley from an “overweight” rating to an “equal weight” rating in a report released on Monday, Marketbeat reports.
Other equities research analysts have also issued research reports about the stock. Royal Bank Of Canada restated a “hold” rating and issued a $44.00 target price on shares of Fresenius Medical Care in a research note on Wednesday, September 13th. Zacks Investment Research lowered shares of Fresenius Medical Care from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, August 16th. Finally, DZ Bank restated a “buy” rating on shares of Fresenius Medical Care in a research note on Monday, November 13th. Two analysts have rated the stock with a sell rating, three have issued a hold rating and four have given a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average price target of $48.50.
Shares of Fresenius Medical Care (NYSE:FMS) traded up $0.37 during trading on Monday, hitting $51.65. 167,100 shares of the stock were exchanged, compared to its average volume of 180,936. The firm has a market cap of $31,802.04, a price-to-earnings ratio of 23.16, a PEG ratio of 2.32 and a beta of 0.45. The company has a current ratio of 1.22, a quick ratio of 0.98 and a debt-to-equity ratio of 0.55. Fresenius Medical Care has a 1-year low of $39.46 and a 1-year high of $51.66.
Fresenius Medical Care Company Profile
Fresenius Medical Care AG & Co KGaA is a kidney dialysis company. The Company provides dialysis care and related services to persons suffering from end-stage renal disease (ESRD), as well as other healthcare services. The Company’s segments include North America Segment, the Europe, Middle East and Africa (EMEA) Segment, the Asia-Pacific Segment and the Latin America Segment.
Receive News & Ratings for Fresenius Medical Care Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care Corporation and related companies with MarketBeat.com's FREE daily email newsletter.